David Silverstein, MD
Dermatology · Ronkonkoma, NYNPI 1295978252
Payments from drug & device makers
What this record shows
This record is dominated by education: $243 of the $357 with a category attached, or 68.1%. Johnson & Johnson accounts for 75.0% of it on its own, with 4 other manufacturers making up the rest. That places this record below the midpoint for dermatology clinicians in NY, where the typical reported total is $2,360.
Across 8 payments — averaging $44.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$268
- Novartis$32
- Fresenius Kabi USA, LLC$26
- Sun Pharmaceutical Industries Inc.$17
- UCB, Inc.$15
Across 8 payments — averaging $5882.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$31K
- Amgen$16K
What the payments were for
- Food & beverage$11432%
- Education$24368%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 4 | $268 |
| Novartis | 1 | $32 |
| Fresenius Kabi USA, LLC | 1 | $26 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| UCB, Inc. | 1 | $15 |
How this compares
$357 in reported general payments places this provider in the 20th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 17 | $123,462 |
| Taltz AutoinjectorIxekizumab | 11 | $72,117 |
| Dupixent SyringeDupilumab | 20 | $68,851 |
| JubliaEfinaconazole | 14 | $18,778 |
| Tacrolimus | 69 | $13,375 |
| Metronidazole | 179 | $8,800 |
| Ketoconazole | 390 | $7,992 |
| Clobetasol Propionate | 165 | $6,247 |
| Doxycycline Hyclate | 158 | $4,627 |
| Clindamycin Phosphate | 51 | $2,508 |
| Triamcinolone Acetonide | 158 | $2,200 |
| Acitretin | 11 | $2,018 |
| Fluorouracil | 27 | $1,888 |
| Calcipotriene | 16 | $1,529 |
| Tretinoin | 23 | $1,378 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Ronkonkoma
- Alexandra GolantNew York$3.6M
- David CohenNew York$3M
- Michael CameronNew York$2.6M
- Saakshi KhattriNew York$2.4M
- Amy WechslerNew York$2.4M
- Jeffrey WeinbergKew Gardens$2.3M
- Joshua ZeichnerNew York$2.1M
- Russell CohenOceanside$2.1M
- Jeffrey LaducaAuburn$1.9M
- Emma GuttmanNew York$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.